BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-726@pharmaconomics
DTSTAMP:20260707T034703Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:MIST Phase 3 — etripamil (estimated date)
DESCRIPTION:Phase 3 trial results for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) are due ~ Jun 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1408443/000110465926059780/tm2614433d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/726
URL:https://www.pharmaconomics.com/e/726
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MIST catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR